{"id":585905,"date":"2025-11-22T02:41:23","date_gmt":"2025-11-22T02:41:23","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/585905\/"},"modified":"2025-11-22T02:41:23","modified_gmt":"2025-11-22T02:41:23","slug":"human-challenge-trials-gain-ground-in-europe-japan-cautious","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/585905\/","title":{"rendered":"Human challenge trials gain ground in Europe; Japan cautious"},"content":{"rendered":"<p><strong>CHIM <\/strong>trials, also known as human challenge studies, are considered a more efficient way to evaluate the efficacy and safety of candidate medicines than conventional methods.<\/p>\n<p>In Japan, concerns over risks, including severe illness and potential long-term effects, have fueled strong opposition, and the government remains cautious about adopting the approach.<\/p>\n<p>CHIM trials can shorten development timelines and reduce participant numbers by not waiting for participants to encounter the pathogen in everyday life, unlike conventional trials.<\/p>\n<p>In a late August interview with <strong>Jiji Press<\/strong> and other media outlets, Dr <strong>Pierre Van Damme<\/strong>, director of <strong>Vaccinopolis<\/strong>, a clinical trial facility operated by the University of Antwerp&#8217;s Centre for the Evaluation of Vaccination, underscored the value of CHIM trials. &#8220;If we had developed vaccines earlier, we would have reduced mortality even more,&#8221; Van Damme said of the Covid-19 pandemic. Vaccinopolis houses 30 beds dedicated to CHIM, the largest capacity worldwide.<\/p>\n<p>Van Damme noted that conventional trials often enrol 1,000 to 40,000 participants and run for several years, whereas CHIM studies can reduce this to 20 to 200 participants over just a few months.<\/p>\n<p>            <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/11\/lg-webp.webp\" alt=\"Human challenge trials gain ground in Europe; Japan cautious\" class=\"img-fluid w-100 showcaption-false\" style=\"width: 800px; height: 537px;\" width=\"800\" height=\"537\" loading=\"lazy\"\/>\n        <\/p>\n","protected":false},"excerpt":{"rendered":"CHIM trials, also known as human challenge studies, are considered a more efficient way to evaluate the efficacy&hellip;\n","protected":false},"author":2,"featured_media":585906,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5174],"tags":[184762,2000,299,5187,20675,2122],"class_list":{"0":"post-585905","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eu","8":"tag-controlled","9":"tag-eu","10":"tag-europe","11":"tag-european","12":"tag-infection","13":"tag-japan"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115591046387314258","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/585905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=585905"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/585905\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/585906"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=585905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=585905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=585905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}